PHFI rejected HPV vaccine project proposal

Said it failed to state ethical aspects involved in the study

February 18, 2011 12:25 am | Updated 12:25 am IST - NEW DELHI:

The proposal for conducting the now controversial “Post-licensure observational study of Human Papilloma Virus (HPV) vaccination: Demonstration Project,” carried out by a non-governmental organisation PATH for two major pharmaceutical companies, had been turned down by the Public Health Foundation of India (PHFI) as it failed to state the ethical aspects involved in it.

The PHFI had received the proposal for conducting the study from the Indian Institute of Public Health at Gandhi Nagar (Gujarat) but the Institutional Ethics Committee of the Foundation rejected it on the grounds that it was “based on the assumption that no ethical issues arise with regard to undertaking the HPV vaccine demonstration project.''

“It was based on an assumption that the vaccine was safe and efficacious,'' Srinath Reddy, president of the PHFI told The Hindu adding that the ethical aspects of the study were not stated in the proposal.

Addressing a press conference here on Thursday, the Jan Swasthya Abhiyan and the All-India Democratic Women's Association (AIDWA), and SAMA, said the interim report of the three-member committee, constituted by the Centre to look into various aspects of the project that had been suspended in April following the death of six girls, had let off the hook all those involved in the project by declaring the deficiencies in the project as “minor'' and not “wilful or fully anticipatable'' and stating that “since there does not appear to be any mal-intention, no responsibility could be fixed.''

Dangerous precedent

“Since violations have occurred at all levels of project, we demand that all involved must be considered culpable, and appropriate punitive action taken. To say that responsibility cannot be fixed on any one individual or organisation is a dereliction of duty, and a convenient excuse for irresponsible and unethical conduct, thus setting a dangerous precedent, Sarojini N. of SAMA, said.

Communist Party of India (Marxist) MP Brinda Karat who had raised the issue last year, said the government should take stern action against the wrongdoers. “There must be a further scrutiny of the role of the Drugs Controller General of India and the Indian Council of Medical Research as the primary institutions involved in the project. Appropriate action should also be taken against the NGOs concerned,'' she said while demanding compensation for all the subjects who were victims to the vaccine programme without their consent.

Ms. Karat has also written to the Union Health and Family Welfare Minister Ghulam Nabi Azad in connection with the interim report pointing out that there was nothing minor about the various deficiencies noted by the committee.

These were major violations and exoneration of those responsible would set a dangerous precedent. Indeed the committee members had not done any credit to their reputation by such an “outrageous'' recommendation, she said.

Aim to influence government

The committee, perhaps, in spite of itself and the many acts of omission and commission in its report has raised serious issues about the project. “Regardless of the intention there was a conflict of interest and all the deficiencies in the design of the project as well as the conduct of the project could have been precisely because the main aim was to influence government to include the vaccine in the public health programme,'' she said.

“Despite stating the fact that the vaccine for the study was provided by manufacturers free of cost does raise the concern about undeclared conflict of interest since the results of the study may be used to influence the decision by the government, the committee fails to build upon this significant and alarming aspect,” Ms. Karat said.

Quoting from the report that more than a quarter of clinical trials in the world were now being conducted in India, Jan Swasthya Abhiyan said concurrently the Ministry of Health and Family Welfare claimed that there had been a manifold rise in the number of deaths among clinical trial subjects in the past few years.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.